INSPIRE MEDICAL (INSP) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Inspire Medical Systems, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Inspire Medical Systems, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Inspire has engaged in unlawful business practices that may have led to losses for its stockholders [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance - On August 5, 2025, Inspire announced better-than-expected second quarter fiscal 2025 results but significantly reduced its full-year guidance from earnings of $2.20 - $2.30 on revenue of $940 million - $955 million to earnings of $0.40 - $0.50 on revenue of $900 million - $910 million [6]. - This revision followed a previous increase in earnings guidance just one quarter prior, indicating a sudden downturn in expectations [6]. - Management attributed the guidance cut to slowdowns in the rollout of Inspire V, citing issues such as incomplete training and onboarding, customer delays, technical Medicare adoption delays, and ongoing high demand for Inspire IV devices [6]. - Following this announcement, Inspire's stock price dropped by $46.44 to open at $83.51 per share [6].